Diabetes

Advances in Type 1 and Type 2 Diabetes

Advances in Type 1 and Type 2 Diabetes aims to provide an in-depth understanding of the most recent scientific, clinical, and technological developments in the prevention, diagnosis, and treatment of these two major forms of diabetes. Type 1 diabetes (T1D), an autoimmune condition primarily diagnosed in children and young adults, and Type 2 diabetes (T2D), a chronic metabolic disorder often linked with lifestyle and genetic factors, continue to pose significant global health challenges. In recent years, tremendous progress has been made in understanding the genetic and environmental triggers of Type 1 diabetes. The identification of autoantibodies and specific risk markers has helped in predicting disease onset, enabling early intervention strategies. Immune-modulating therapies, including antigen-specific immunotherapy and checkpoint inhibitors, are being actively explored to delay or prevent the progression of T1D. Additionally, the development of closed-loop insulin delivery systems (artificial pancreas) and advancements in continuous glucose monitoring (CGM) technologies have significantly improved the quality of life for people living with T1D.For Type 2 diabetes, a complex interplay of insulin resistance, pancreatic beta-cell dysfunction, and metabolic dysregulation is central to its pathogenesis.